Over 30 Phase 2 and Phase 3 clinical trials were used in training this model, spanning 14 distinct therapeutic agents, including THF inhibitors, IL-17 inhibitors, IL-23 inhibitor, as well as JAK and TYK2 inhibitors in multiple patient populations (ex: naive to biologic therapies).